Infusion reactions to monoclonal antibodies for solid tumors: immunologic mechanisms and risk factors.

Christine H. Chung, Bert H. O'Neil

Research output: Contribution to journalArticle


The development of monoclonal antibodies targeting various receptors and ligands has been a significant advance in cancer therapy. These monoclonal antibodies are generally well tolerated. A subset of patients, however, experience infusion reactions with symptoms ranging from mild to life-threatening anaphylaxis. The underlying mechanisms of these reactions are not well characterized. In this review, current findings in clinical risk factor assessments and known mechanisms of these infusion reactions are discussed.

Original languageEnglish (US)
Pages (from-to)14-17
Number of pages4
Issue number2 Suppl 1
StatePublished - Feb 2009
Externally publishedYes


ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this